Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Genentech Inc | 1,160 |
| 2 | AbbVie Inc | 533 |
| 3 | F Hoffmann La Roche AG | 527 |
| 4 | Merck Sharp & Dohme LLC | 431 |
| 5 | Novartis AG | 255 |
| 6 | Vertex Pharmaceuticals Inc | 202 |
| 7 | Bayer Pharma AG | 182 |
| 8 | Array Biopharma Inc | 178 |
| 9 | MedImmune Ltd | 152 |
| 10 | Pfizer Inc | 142 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 17,186 |
| 2 | A61K | Medicinal preparations | 15,394 |
| 3 | C07D | Heterocyclic compounds | 8,295 |
| 4 | C07K | Peptides | 6,282 |
| 5 | G01N | Investigating / analysing materials | 2,458 |
| 6 | C12N | Microorganisms, enzymes | 2,426 |
| 7 | C12Q | Measuring/testing involving enzymes | 1,185 |
| 8 | Y02A | Climate change adaptation | 1,139 |
| 9 | C07C | Acyclic and carbocyclic compounds | 692 |
| 10 | C07B | General methods of organic chemistry | 610 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionMost-cited patents
Patents ranked by forward citations reveal the foundational inventions the field continues to build on.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| ANTICANCER COMBINATION THERAPY USING SUNITINIB MALATE | 2006 | Pfizer Corp Belgium | 39 |
| SUNITINIB HEMI-L-MALATE, POLYMORPHS AND PREPARATION THEREOF, POLYMORPHS OF RACEMIC SUNITINIB MALATE, COMPOSITINS CONTAINING SUNITINIB BASE AND MALIC ACID AND PREPARATION THEREOF | 2009 | Teva Pharmaceutical Industries Ltd | 26 |
| PROCESS FOR PREPARATION OF SUNITINIB MALATE AND SALTS THEREOF | 2012 | BHIRUD, SHEKHAR BHASKAR | 12 |
| NEW CRYSTAL FORM OF SUNITINIB MALATE | 2010 | Lek Pharmaceuticals dd | 10 |
| Anticancer combination therapy using sunitinib malate | 2008 | Pfizer Inc | 10 |
Where research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Renal cell carcinoma treatment | 65 |
| 2 | Gastrointestinal Tumor Research and Treatment | 12 |
| 3 | Colorectal Cancer Treatments and Studies | 5 |
| 4 | Angiogenesis and VEGF in Cancer | 4 |
| 5 | Neuroendocrine Tumor Research Advances | 4 |
| 6 | Sarcoma Diagnosis and Treatment | 4 |
| 7 | HER2/EGFR in Cancer Research | 2 |
| 8 | Hepatocellular Carcinoma Treatment and Prognosis | 2 |
| 9 | Lung Cancer Treatments and Mutations | 2 |
| 10 | Pancreatic and Hepatic Oncology Research | 2 |
Technology trend analysis
Cypris uses AI to connect emerging research themes to IP activity, commercialization signals, and underexplored opportunity areas.
See Cypris in actionWho's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Robert J. Motzer | Memorial Sloan Kettering Cancer Center | 136 |
| 2 | Brian I. Rini | Cleveland Clinic | 133 |
| 3 | Toni K. Choueiri | Dana-Farber Cancer Institute | 87 |
| 4 | Bernard Escudier | Institut Gustave Roussy | 71 |
| 5 | Camillo Porta | University of Pavia | 55 |
| 6 | Alain Ravaud | Hôpital Saint-André | 38 |
| 7 | Thomas Powles | Queen Mary University of London | 38 |
| 8 | Stéphane Oudard | Hôpital Européen Georges-Pompidou | 34 |
| 9 | David F. McDermott | Beth Israel Deaconess Medical Center | 28 |
| 10 | Laurence Albigès | Institut Gustave Roussy | 26 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma | 2007 | 5768 | Renal cell carcinoma treatment |
| Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma | 2018 | 4692 | Cancer Immunotherapy and Biomarkers |
| Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma | 2019 | 3438 | Cancer Immunotherapy and Biomarkers |
| Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial | 2006 | 2607 | Gastric Cancer Management and Outcomes |
| Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma | 2019 | 2569 | Pancreatic and Hepatic Oncology Research |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular composition of Sutent?
Which organizations hold the most patents related to Sutent?
What are the primary clinical applications documented for Sutent in the research literature?
Who are the leading clinical researchers publishing on Sutent?
What is the scale of intellectual property and scientific publication activity around Sutent?